Arcellx, Inc.
$115
▲
0.02%
2026-04-22 10:12:13
www.arcellx.com
NMS: ACLX
Explore Arcellx, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.73 B
Current Price
$115
52W High / Low
$115.13 / $47.86
Stock P/E
—
Book Value
$6.95
Dividend Yield
—
ROCE
-50.64%
ROE
-53.42%
Face Value
—
EPS
$-4.07
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
209
Beta
0.25
Debt / Equity
12.9
Current Ratio
4.43
Quick Ratio
4.44
Forward P/E
-66.29
Price / Sales
301.32
Enterprise Value
$6.32 B
EV / EBITDA
-25.64
EV / Revenue
283.44
Rating
Hold
Target Price
$111.07
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Theravance Biopharma, Inc. | $16.72 | 8.29 | $877.44 M | — | -0.81% | 44.84% | $21.03 / $8.33 | $5.81 |
| 2. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 3. | Eledon Pharmaceuticals, Inc. | $4.14 | — | $314.03 M | — | -55.26% | -35.79% | $4.6 / $1.35 | $1.81 |
| 4. | Tenaya Therapeutics, Inc. | $0.74 | — | $169.71 M | — | -70.98% | -83.84% | $2.35 / $0.36 | $0.57 |
| 5. | Dyne Therapeutics, Inc. | $20.02 | — | $3.37 B | — | -41.2% | -55.71% | $25 / $7.38 | $5.89 |
| 6. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
| 7. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.65 M | 4.95 M | 7.55 M | 8.13 M | 15.27 M | — |
| Operating Profit | -63.68 M | -61.78 M | -58.73 M | -68.9 M | -53.15 M | — |
| Net Profit | -58.11 M | -55.78 M | -52.77 M | -62.27 M | -47.08 M | — |
| EPS in Rs | -0.99 | -0.95 | -0.9 | -1.06 | -0.81 | -0.48 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 22.29 M | 107.94 M | 110.32 M | 0 M |
| Operating Profit | -253.08 M | -137.57 M | -89.88 M | -191.26 M |
| Net Profit | -228.93 M | -107.35 M | -70.69 M | -188.68 M |
| EPS in Rs | -3.91 | -1.84 | -1.21 | -3.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 603.99 M | 711.33 M | 825.13 M | 313.82 M |
| Total Liabilities | 201.64 M | 256.54 M | 339.75 M | 108.86 M |
| Equity | 402.35 M | 454.79 M | 485.38 M | 204.95 M |
| Current Assets | 462.18 M | 599.31 M | 716.36 M | 266.86 M |
| Current Liabilities | 104.2 M | 125.41 M | 118.24 M | 56.69 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -210.26 M | -83.47 M | 207.57 M | -99.3 M |
| Investing CF | 86.3 M | -183.04 M | -154.51 M | -117.67 M |
| Financing CF | 98.53 M | -24.09 M | 279.16 M | 252.62 M |
| Free CF | -212.59 M | -96.9 M | 186.15 M | -101.58 M |
| Capex | -2.33 M | -13.43 M | -21.43 M | -2.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -2.16% | — | — | — |
| Earnings Growth % | -51.86% | 62.53% | — | — |
| Profit Margin % | -99.46% | -64.08% | — | — |
| Operating Margin % | -127.46% | -81.47% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -91.78% | -58.15% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.